EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer

Min-Hyun Baek iD, Lei Chen iD, Cumhur Tekin iD, Razvan Cristescu iD, Xiao Yang Jin iD, Changxia Shao iD, Soo Yeon Ihm iD, Petar Jelinic iD, Jeong-Yeol Park iD

Journal of Gynecologic Oncology · 2024

DOI: 10.3802/jgo.2024.35.e105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Min-Hyun Baek und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gynecologic Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea. Hauptthemen laut MEDLINE: B7-H1 Antigen, Uterine Cervical Neoplasms, Mutation, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck Sharp & Dohme LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the prevalence and prognostic role of programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) in patients with non-immunotherapy-treated advanced cervical cancer. METHODS: Clinical data were retrospectively collected from medical records between January 1, 2008, and December 31, 2016, at Asan Medical Center (Korea); archived tumor samples were assessed for PD-L1 expression (combined positive score [CPS] ≥1) and TMB (≥175 mutations/exome). Overall survival (OS) was defined as time from advanced diagnosis or initiation of first-line or second-line systemic therapy until death/last follow-up. The association of OS with PD-L1 expression and TMB were analyzed using the log-rank test and Cox proportional hazards model adjusted for covariates. RESULTS: Of 267 patients, 76.0% had squamous cell carcinoma (SCC), 24.0% had adenocarcinoma (AC)/adenosquamous carcinoma (ASC), 64.4% had PD-L1 CPS ≥1, and 32.6% had TMB ≥175 mutations/exome. PD-L1 CPS ≥1 and TMB ≥175 mutations/exome were more prevalent in SCC than in AC/ASC (73.9% and 37.2% vs. 34.4% and 17.7%). There was no association between OS and PD-L1 expression (CPS ≥1 vs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenUterine Cervical NeoplasmsMutationNeoplasm Recurrence, LocalHumansFemaleMiddle AgedRetrospective StudiesPrognosisAdultAgedCarcinoma, Squamous CellPrevalenceAdenocarcinomaCarcinoma, AdenosquamousBiomarkers, Tumor

Stichwörter der Autor:innen

Cervical CancerPD-L1 Protein

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Center for Gynecologic Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
  • Merck & Co., Inc., Rahway, NJ, USA.
  • MSD Korea, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. catgut1-0@hanmail.net.

ORCID-Profile: Min-Hyun Baek, Lei Chen, Cumhur Tekin, Razvan Cristescu, Xiao Yang Jin, Changxia Shao, Soo Yeon Ihm, Petar Jelinic, Jeong-Yeol Park

Förderung

  • Merck Sharp & Dohme LLC

Zitieren

APA

Baek, M. H., Chen, L., Tekin, C., Cristescu, R., Jin, X. Y., Shao, C., Ihm, S. Y., Jelinic, P., & Park, J. Y. (2024). Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e105

Vancouver

Baek MH, Chen L, Tekin C, Cristescu R, Jin XY, Shao C, et al. Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e105

BibTeX
@article{Baek2024,
  author = {Baek, Min-Hyun and Chen, Lei and Tekin, Cumhur and Cristescu, Razvan and Jin, Xiao Yang and Shao, Changxia and Ihm, Soo Yeon and Jelinic, Petar and Park, Jeong-Yeol},
  title = {Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer},
  journal = {Journal of Gynecologic Oncology},
  year = {2024},
  doi = {10.3802/jgo.2024.35.e105}
}
Kostenlos starten →